Positive 32-Week Findings Seen With Tralokinumab for AD on the Hands
Atopic dermatitis (AD) patients with moderate-to-severe hand involvement taking tralokinumab (Adbry, LEO Pharma) showed sustained improvements out to 32 weeks, according to topline results from the Phase 3b ADHAND trial.